Ownership / Coeptis Therapeutics Holdings, Inc. | Tables in SEC filings

COEPW Coeptis Therapeutics Holdings, Inc.

IPO registration (amended)


	PREFERRED STOCK			COMMON STOCK			ADDITIONAL PAID-IN		SHARES		SUBSCRIPTION		ACCUMULATED		TOTAL COEPTIS		NON- CONTROLLING		TOTAL
	SHARES	AMOUNT		SHARES	AMOUNT		CAPITAL		SUBSCRIBED		RECEIVABLE		DEFICIT		EQUITY		INTERESTS		EQUITY

BALANCE AT DECEMBER 31, 2023	–	$	–	35,331,036	$	3,533	$	91,666,691	$	–	$	(3,500,000)	$	(87,356,260)	$	813,964	$	–	$	813,964

Shares issued for non-employee services	–		–	1,096,381		110		541,640		–		–		–		541,750		–		541,750

Warrants issued for cash	–		–	–		–		500,000		–		–		–		500,000		–		500,000

Warrants issued for services	–		–	–		–		8,150		–		–		–		8,150		–		8,150

Warrants issued in exchange for note receivable	–		–	–		–		1,900,000		–		(2,000,000)		–		(100,000)		–		(100,000)

Stock based compensation	–		–	–		–		96,889		–		–		–		96,889		–		96,889

Net loss	–		–	–		–		–		–		–		(3,001,388)		(3,001,388)		–		(3,001,388)

BALANCE AT MARCH 31, 2024	–	$	–	36,427,417	$	3,643	$	94,713,370	$	–	$	(5,500,000)	$	(90,357,648)	$	(1,140,635)	$	–	$	(1,140,635)

Shares issued for services	–		–	1,850,000		185		558,165		–		–		–		558,350		–		558,350

Shares issued for the conversion of debt	506		1	1,441,176		144		951,855		–		–		–		952,000		–		952,000

Preferred share offering	3,794		1	–		–		3,661,505		50,000		(2,100,000)		–		1,611,506		132,494		1,744,000

Stock based compensation	–		–	–		–		611,570		–		–		–		611,570		–		611,570

Net loss	–		–	–		–		–		–		–		(3,035,345)		(3,035,345)		–		(3,035,345)

BALANCE AT JUNE 30, 2024	4,300	$	2	39,718,593	$	3,972	$	100,496,465	$	50,000	$	(7,600,000)	$	(93,392,993)	$	(442,554)	$	132,494	$	(310,060)

Shares issued for services	–		–	250,000		25		49,475		–		–		–		49,500		–		49,500

Preferred share offering	1,525		–	–		–		1,499,810		(50,000)		–		–		1,449,810		25,190		1,475,000

Relief of subscription receivable	–		–	–		–		–		–		5,500,000		–		5,500,000		–		5,500,000

Stock based compensation	–		–	–		–		96,891		–		–		–		96,891		–		96,891

Net loss	–		–	–		–		–		–		–		(1,828,914)		(1,828,914)		–		(1,828,914)

BALANCE AT SEPTEMBER 30, 2024	5,825	$	2	39,968,593	$	3,997	$	102,142,641	$	–	$	(2,100,000)	$	(95,221,907)	$	4,824,733	$	157,684	$	4,982,417

Schedule of changes in fair value of warrant liabilities
	Private Placement		Public		Warrant Liabilities
Fair value as of December 31, 2023	$	324,750	$	232,500	$	557,250
Change in valuation inputs		6,375		(41,250)		(34,875)
Fair value as of March 31, 2024	$	331,125	$	191,250	$	522,375
Change in valuation inputs		115,500		33,750		149,250
Fair value as of June 30, 2024	$	446,625	$	225,000	$	671,625
Change in valuation inputs		(237,000)		(112,500)		(349,500)
Fair value as of September 30, 2024	$	209,625	$	112,500	$	322,125

Schedule of stock option activity
	Shares Underlying Options		Weighted Average Exercise Price		Weighted Average Contractual Life (Years)		Intrinsic Value
Outstanding at December 31, 2023		1,757,500	$	2.01		7.97	$	–
Granted		2,400,000		0.31		10.00		–
Forfeited		(100,000)		10.00		–		–
Exercised		–		–		–		–
Outstanding at September 30, 2024		4,057,500	$	0.81		8.89	$	–

Schedule of changes in fair value of warrant liabilities
	Private Placement		Public		Warrant Liabilities
Fair value as of December 31, 2022	$	375,000	$	750,000	$	1,125,000
Change in valuation inputs		1,012,500		375,000		1,387,500
Fair value as of March 31, 2023		1,387,500		1,125,000		2,512,500
Change in valuation inputs		75,000		(600,000)		(525,000)
Fair value as of June 30, 2023		1,462,500		525,000		1,987,500
Change in valuation inputs		(1,253,625)		(355,500)		(1,609,125)
Fair value as of September 30, 2023		208,875		169,500		378,375
Change in valuation inputs		115,875		63,000		178,875
Fair value as of December 31, 2023	$	324,750	$	232,500	$	557,250

Name of Selling Stockholder	Number of Shares of Common Stock Beneficially Owned Prior to Offering			Maximum Number of Shares of Common Stock to be Sold in this Offering			Number of Shares of Common Stock Beneficially Owned After Offering		Percentage of Shares Beneficially Owned after Offering
YA II PN, LTD (3)		101,877	(2)		3,819,349	(3)		0		0%
AMLS Holdings LLC		145,000	(4)		50,000			95,000		2.53%
Purple Biotech Ltd. (5)		50,000			50,000			0		0%

Table search / Ownership / Coeptis Therapeutics Holdings, Inc.

240 results

Top filers

Top filing types

Recent filing years